Latest Safety News

Robex Resources confirms steady progress at its Kiniero Gold Project in Guinea, maintaining schedule and budget for first gold production in late 2025. Key construction milestones and drilling activities highlight the project’s momentum.

Metals X Limited reported a robust half-year to June 2025 with profit after tax soaring 256% to $52.9 million, driven by higher tin sales and prices from its Renison joint venture. The company also progressed key projects and deepened strategic investments while reinforcing its ESG and safety frameworks.

Supply Network Limited reported a robust 15.5% revenue increase to $349.9 million and a 21.2% rise in profit after tax to $40 million for FY2025, alongside a higher fully franked final dividend of 38 cents per share.

Symal Group has outperformed its FY25 earnings forecasts, driven by strong project margins and strategic acquisitions, setting a robust foundation for FY26 growth.

Symal Group Limited reports a strong first year as an ASX-listed company, exceeding earnings forecasts and advancing its growth through key acquisitions and sustainability initiatives.

K&S Corporation reported a 9% decline in underlying profit before tax for FY2025, alongside a 9.7% drop in revenue, as it invests heavily in property and terminal upgrades while navigating safety regulatory pressures.

Desane Group Holdings Limited reported a strong FY25 with net profit after tax doubling to $3.3 million, supported by a $6.2 million uplift in property valuations and key lease extensions securing future rental income.

Asset Vision reported robust FY25 results with significant revenue and cash flow growth, achieving a debt-free status while advancing its AI-powered asset management platform.

GR Engineering Services Limited has reported a robust FY25 financial performance with increased revenue, profit, and dividends, supported by a solid order book and ongoing major projects.

GR Engineering Services Limited reported a 12.96% increase in revenue to $479 million for FY25, alongside a 9.7% rise in net profit after tax to $34.2 million. The company declared a fully franked final dividend of 12 cents per share, signaling confidence in its robust project pipeline and financial position.

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.